In particular, albeit TRAIL has been and still continues to be of major interest in oncology, due to its selective anti-tumor properties and its role in anti-tumor immunity [145,146,147], clinical trials aiming at targeting DR4 or DR5 have been so far unsatisfactory [148,149]. Here, TNFRSF10A is linked to neoplasm.